West Bloomfield, MI: The administration of a proprietary, water-soluble CBD tablet mitigates neuropathic foot pain compared to placebo, according to randomized clinical trial data published in the Journal of Diabetes & Metabolism.
Researchers affiliated with Pure Green Pharmaceuticals assessed the efficacy of sublingual CBD tablets (20mg) versus placebo in a cohort of subjects with painful diabetic peripheral neuropathy (pDPN) pain in their feet. Subjects were administered either the active drug or a placebo three times per day for 28 days.
Those taking the active drug reported significant reductions in pain compared to placebo and no adverse side-effects. Subjects taking CBD also reported improvements in their sleep quality and reduced levels of anxiety.
Authors concluded: “This 28-day trial revealed statistically and clinically significant improvement in pain and a clinically significant improvement in sleep quality and in anxiety reduction for those in the CBD treatment group. Additionally, subjects taking CBD affirmed these results by having a statistically significant greater response to treatment as compared with subjects taking placebo. The benefit of this study demonstrates that the sublingual 20 mg CBD tablet should be considered as a safe and effective treatment for pDPN.”
Numerous placebo-controlled clinical trials similarly document the ability of whole-plant cannabis to mitigate neuropathic pain in a wide range of patient populations, including in subjects with HIV and diabetes.
Full text of the study, “Cannabidiol for the treatment of painful diabetic peripheral neuropathy of the feet: A placebo-controlled, double-blind, randomized trial,” appears in the Journal of Diabetes & Metabolism. Additional information on cannabinoids and neuropathy is available from NORML.